Our collaboration partner SB Drug Discovery is offering stably-transfected cells for Assays on Nanion's Instruments

logo sb

SB Drug Discovery is a specialist ion channel CRO offering the most comprehensive portfolio of ion channel cell lines and screening assays for drug discovery research. SB’s extensive panel comprises more than 150 ion channel targets and over 200 ion channel assays covering a broad range of ion channel families. Their validated assays utilize fluorescence, manual patch clamp and automated electrophysiology platforms and can be customized to meet individual customer needs.

Whether you require HTS or routine lead optimization for your target of interest or selectivity profiling using a standard or customized panel of your choice for safety liabilities, SB’s expert team of Project Leaders, electrophysiologists and highly experienced scientists are on hand to design and manage your ion channel projects.

SB also specialises in custom ion channel cell line generation including generation of multi-target cell lines and species orthologs. Their cell biology team has extensive expertise in cell line generation and has optimised streamline processes to enable rapid generation of high quality ion channel reagents:

  • Custom ion channel cell line generation

  • Off-the-shelf cell lines 


The following cells were validated on Nanion's Instruments:


Collaborative Activities and projects with SB Drug Discovery

2018 - Expression and pharmacology of GluA2-containing AMPA receptors in cell lines and stem cell-derived neurons

icon pap   Port-a-Patch,   icon pl   Patchliner and   icon sp96   SyncroPatch 384PE poster, Europhysiology Meeting 2018  logo pdf   (0.9 MB)

2017 - lnvestigation of the Ion Channels hTMEM16A/Ano1 and TRPC5 and their Modulation by Intracellular Calcium

icon sp96   SyncroPatch 384PE poster, BPS Meeting 2017  logo pdf   (1.3 MB)

AMPA receptor (GluA2) - Activation, potentiation and inhibition of AMPA receptors on the SyncroPatch 384PE

icon sp96   SyncroPatch 384PE application note:   logo pdf   (3.1 MB)
Cells were kindly provided by SB Drug Discovery.

AMPA Receptor (GluA2) - Activation by Glutamate

icon sp96   GluR2 PE DataSyncroPatch 384PE data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was activated using different concentrations of glutamate (1 µM - 100 µM). Measured on the SyncroPatch 384PE the whole cell patch methodology and multi-hole chips were used.
The lower two images are displaying screenshots of single cell currents after repetitive glutamate applications:
Left: The same concentration of Glutamate was applied three times.
Right: Four different Glutamate concentrations were applied in a cumulative manner.

AMPA Receptor (GluA2) - Pharmacology

icon sp96   GluR2 PE Data PharmacologySyncroPatch 384PE data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was analyzed using different positive and negative allosteric modulators (CNQX, LY404187, LY395153, CP465022, Cyclothiazide). After activating the receptor by application of Glutamate, the modulating compound plus glutamate was applied afterwards. Measured on the SyncroPatch 384PE the whole cell patch methodology and multi-hole chips were used.
The lower images on the left hand side are displaying a screenshot of a current after application of the positive modulator LY404187. The EC50 was determined as 379 nM.

AMPA Receptor (GluA2) - Cumulative Concentration Response

icon sp96   GluA2 GluCRC SP384PE SBSyncroPatch 384PE data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2)was activated by increasing concentrations of glutamate on the SyncroPatch 384PE. L-glutamate was applied for approximately 500 ms in increasing concentrations (A) and a cumulative concentration response curve for glutamate was constructed for 222 wells (C).
The online analysis values peak amplitude and area under the curve (AUC) are shown versus time in Panel B. The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).

AMPA Receptor (GluA2) - Inhibition by CNQX

icon pl  GluA2_CNQX_SB_PLPatchliner data and applications:
Cells were kindly provided by SB Drug Discovery.

The AMPA receptor (GluA2) was blocked by CNQX on the Patchliner. CNQX was pre-incubated and then co-applied with glutamate. CNQX blocked the GluA2-mediated response in a concentration dependent manner and the potency was dependent on glutamate concentration (left). Exemplar GluA2-mediated responses are shown on the right activated by 100 µM glutamate and inhibited by increasing concentrations of CNQX.

AMPA Receptor (GluA2) - Fast Perfusion with the Port-a-Patch

icon pap   Port-a-Patch data and applications:
Cells were kindly provided by SB Drug Discovery.

GluA2 GluCRC PaP SB

The AMPA receptor (GluA2) was activated by increasing concentrations of glutamate on the Port-a-Patch. L-glutamate was applied for approximately 500 ms in increasing concentrations (left) and a cumulative concentration response curve for glutamate was constructed for 8 cells (right). The fast activation of GluA2 could be captured at higher concentrations (inset; 1 mM).

 

AMPA Receptor (GluA2) - Reproducible Responses

icon pap   GluA2 Stability PaPPort-a-Patch data and applications:
Cells were kindly provided by SB Drug Discovery.

GluA2 reproducibly recorded on the Port-a-Patch. L-glutamate was applied for 500 ms and this was repeated six times in the same cell showing reproducible responses.

Dr. David Dalrymple - Statement about the SyncroPatch 384PE

icon sp96   “As a leading ion channel contract research organization running one of the most comprehensive ranges of ion channel assays, SB Drug Discovery has been impressed with the flexibility and reliability of the SyncroPatch 384PE, enabling development of a range of varied and complex ion channel assay for both high throughput screening and hit-to-lead profiling purposes. The SyncroPatch has proven to be a crucial addition to SB’s ion channel capabilities and in partnership with expert advice from Nanion’s support team has enabled SB to advance its ion channel capabilities to the forefront of ion channel drug discovery research..“

Dr. David Dalrymple
Business Development Director at SB Drug Discovery

TMEM16A (ANO1) - "Internal perfusion of Ca2+ to activate TMEM16A/ANO1 on the SyncroPatch 384PE"

icon sp96   SyncroPatch 384PE application note   logo pdf   (6.8 MB)
Cells were kindly provided by SB Drug Discovery.

CaV1.2 - "High Throughput Pharmacology of CaV1.2 Channels on Nanion’s SyncroPatch 384PE"

icon sp96   SyncroPatch 384PE application note:   logo pdf   (2.7 MB)
Cells were kindly provided by SB Drug Discovery.  

TREK-1 - "Activation and inhibition of TREK-1 on Nanion’s SyncroPatch 384PE"

icon sp96   SyncroPatch 384PE application note   logo pdf   (6.0 MB)
Cells were kindly provided by SB Drug Discovery.

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok